As one of the leading COVID-19 vaccine manufacturers in China, Sinovac has expanded its annual production capacity to 2 billion doses and offered its inactivated vaccines to over 16 countries and regions. The Global Times reporters Hu Yuwei and Leng Shumei (GT) recently talked to Yin Weidong (Yin), the CEO of the Sinovac, to learn more about his views on vaccine's safety and effectiveness, amid frequently novel coronavirus mutations, and the company's moves in making the vaccine more globally accessible.
Read the interview here.
Refana Inc., is United States registered private corporation dedicated to finding practical and innovative solutions to the world's medical problems. By utilizing a highly collaborative open source system of research and development Refana has been able to attract world leaders in their respective scientific and medical fields to work on these problems. Through this model Refana hopes to greatly accelerate the vaccine development process for Covid-19 and help protect not only the health of the world, but also the economies and stability of nations at risk.